When did Supernus go public?
Supernus Pharmaceuticals, Inc. officially completed its initial public offering and began trading its common stock on the NASDAQ Global Select Market under the ticker symbol SUPN in May 2012. The specialty pharmaceutical enterprise, dedicated to developing and commercializing novel products for the treatment of central nervous system disorders, utilized proceeds from its public market debut to fund advanced clinical development pipelines, scale commercial operations, and support regulatory drug approvals.
Related FAQs
Levodopa, frequently administered in combination with carbidopa, is universally recognized as the clinical gold standard pharmacological treatment for managing the motor symptoms of Parkinson's disease.
Evaluating the profitability profile of Supernus Pharmaceuticals involves analyzing fluctuating quarterly earnings reports, research and development expenditures, and commercial product sales revenue.
Supernus Pharmaceuticals, Inc. operates as a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
Supernus Pharmaceuticals operates primarily as a specialty pharmaceutical enterprise rather than a traditional early-stage biotechnology research firm.
Supernus Pharmaceuticals is an authentic, publicly traded corporate entity listed on the Nasdaq Global Select Market under the ticker symbol SUPN.
"Swig" is not a widely recognized publicly traded stock ticker, though it is commonly confused with "Swiggy," a major consumer technology company based in India.
The five-two-one rule or similar numerical clinical heuristics for Parkinson's disease assist neurologists and patients in monitoring progressive symptom management, medication timing schedules, and multidisciplinary therapy interventions.
Swire Properties Limited is a major premier developer, owner, and operator of mixed-use commercial and residential properties, primarily centered in Hong Kong and the Chinese mainland.
Supernus Pharmaceuticals has executed key strategic acquisitions to bolster its neurology and neuropsychiatry product portfolio and diversify its revenue streams.
During the course of Joe Biden's presidency, the stock market experienced strong upward momentum alongside broader macroeconomic shifts, with the Dow Jones Industrial Average rising by roughly 40.
Supernus Pharmaceuticals anticipates a progressive future growth outlook driven by the expansion of its specialized neurology and psychiatry product portfolio, including treatments for epilepsy, attention deficit hyperactivity disorder, and centra...
Yes, Stanley Black & Decker (trading under the ticker SWK) has a long-standing corporate history of executing stock splits throughout its multi-decade trajectory as a premier global industrial tool and hardware manufacturer.
Supernus Pharmaceuticals operates in rigorous compliance with federal and international pharmaceutical regulations, medical ethics standards, and corporate compliance frameworks.
Supernus Pharmaceuticals operates in the specialty pharmaceutical sector focusing on central nervous system disorders, encountering competition from numerous established drug developers and generic manufacturers.
Supernus Pharmaceuticals, Inc.
A 70-year-old individual diagnosed with stage 3 chronic kidney disease can often live a normal lifespan, provided the condition is actively managed and monitored through proper lifestyle modifications, blood pressure control, and dietary adjustmen...
Supernus Pharmaceuticals, Inc. was officially founded and established in 2005 through a management buyout of specialty pharmaceutical assets from Shire plc.
Supernus Pharmaceuticals specializes in developing and commercializing specialized central nervous system medications designed to treat psychiatric and neurological disorders.
Supernus Pharmaceuticals maintains a solid reputation within the specialty healthcare and pharmaceutical sector, anchored by its diverse portfolio of FDA-approved medications addressing complex central nervous system disorders.
Actor and Parkinson's disease research advocate Michael J.